**Supplementary file 5.** Clinicopathological parameters per survival tree node in platinum-treated high-grade serous ovarian cancer.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 1 (TC 121 / Neuronal development) |  | Low (#) | % | High (#) | % |
| Stage | 1234 | 141220330 | *5.4**4.6**78**12* | 21293 | *5.7**2.9**83**8.6* |
| Age, mean (range) |  | 59 (23-89) | 64 (33-79) |
| Taxol treated | Yes No | 20752 | *80**20* | 2312 | *66**34* |
| Neo-adjuvant | Yes No | 11248 | *4.2**96* | 134 | *2.9**97* |
| Debulking | OptimalSuboptimal | 140119 | *54**46* | 1817 | *51**49* |
| Series | 1982920565261939899 | 265410169 | *10**21**3.9**65* | 15128 | *2.9**14**2.9**80* |
| 1 year survival (95% CI) | 95% (93-98) | 86% (75-98) |
| 3 year survival (95% CI) | 62% (56-69) | 32% (19-54) |
| 5 year survival (95% CI) | 38% (31-46) | 14% (5-43) |
| Median survival | 1391 (1251-1647) | 671 (610-1159)  |

A. Clinicopathological parameters for subgroups defined by node 1 (TC 121 / Neuronal development)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 2 (Stage) |  | 1-2-3 (#) | % | 4 (#) | % |
| Stage | 1234 | 1412203 | *6.1**5.2**89* | 30 | *100* |
| Age, mean (range) |  | 60 (23-89) | 58 (38-80) |
| Taxol treated | Yes No | 18544 | *81**19* | 228 | *73**27* |
| Neo-adjuvant | Yes No | 6223 | *2.6**97* | 525 | *17**83* |
| Debulking | OptimalSuboptimal | 13297 | *58**42* | 822 | *27**73* |
| Series | 1982920565261939899 | 22468153 | *9.6**20**3.5**67* | 48216 | *13**27**7**53* |
| 1 year survival (95% CI) | 96% (94-99) | 93% (84-100) |
| 3 year survival (95% CI) | 67% (60-74) | 27% (14-53) |
| 5 year survival (95% CI) | 40% (33-49) | 0 (NA-NA) |
| Median survival (95% CI) | 1454 (1342-1769) | 903 (732-1464) |

B. Clinicopathological parameters for subgroups defined by node 2 (Stage)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 3 (Stage) |  | 1-2 (#) | % | 3 (#) | % |
| Stage | 123 | 1412 | *54**46* | 203 | *100* |
| Age, mean (range) |  | 59 (43-77) | 60 (23-89) |
| Taxol treated | Yes No | 197 | *73**27* | 16637 | *82**18* |
| Neo-adjuvant | Yes No | 26 | *100* | 6197 | *3**97* |
| Debulking | OptimalSuboptimal | 242 | *92**8* | 10895 | *53**47* |
| Series | 1982920565261939899 | 28214 | *8**31**8**54* | 20386139 | *10**19**3**69* |
| 1 year survival (95% CI) | 100 (NA-100) | 96% (83-99) |
| 3 year survival (95% CI) | 96% (88-100) | 63% (56-71) |
| 5 year survival (95% CI) | 78% (58-100) | 36% (28-45) |
| Median survival (95% CI) | 3392 (1943-NA) | 1373 (1220-1541) |

C. Clinicopathological parameters for subgroups defined by node 3 (Stage)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 4 (TC 166 / 13q12-q14 / Replication & apoptosis) |  | Low (#) | % | High (#) | % |
| Age, mean (range) |  | 58 (23-80) | 61 (39-89) |
| Taxol treated | Yes No | 7215 | *93**17* | 9422 | *81**19* |
| Neo-adjuvant | Yes No | 384 | *3.4**97* | 3113 | *3**97* |
| Debulking | OptimalSuboptimal | 4047 | *46**54* | 4868 | *41**59* |
| Series | 1982920565261939899 | 16368 | *18**3**78* | 2022371 | *17**19**3**61* |
| 1 year survival (95% CI) | 98% (94-100) | 95% (91-99) |
| 3 year survival (95% CI) | 53% (42-66) | 71% (62-81) |
| 5 year survival (95% CI) | 19% (10-35) | 46% (36-59) |
| Median survival (95% CI) | 1129 (991-1331) | 1662 (1415-2196) |

D. Clinicopathological parameters for subgroups defined by node 4 (TC 166 / 13q12-q14 / Replication & apoptosis)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 5 (TC 247 / 11q13-q14 / Proliferation & immune response) |  | Low (#) | % | High (#) | % |
| Age, mean (range) |  | 59 (39-87) | 65 (41-89) |
| Taxol treated | Yes No | 1858 | *24**76* | 436 | *10**90* |
| Neo-adjuvant | Yes No | 274 | *2.6**97* | 139 | *2.5**98* |
| Debulking | OptimalSuboptimal | 4135 | *54**46* | 2713 | *68**33* |
| Series | 1982920565261939899 | 317353 | *3.9**22**3.9**70* | 17518 | *43**13**45* |
| 1 year survival (95% CI) | 96% (92-100) | 92% (84-100) |
| 3 year survival (95% CI) | 78% (68-88) | 57% (42-78) |
| 5 year survival (95% CI) | 56%% (41-69) | 26% (13-52) |
| Median survival (95% CI) | 2074 (1541-2784) | 1220 (1007-2196) |

E. Clinicopathological parameters for subgroups defined by node 5 (TC 247 / 11q13-q14 / Proliferation & immune response)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 6 (TC 250 / ECM interactions) |  | Low (#) | % | High (#) | % |
| Age, mean (range) |  60 (39-87) | 60 (48-76) |
| Taxol treated | Yes No | 4712 | *80**20* | 116 | *65**35* |
| Neo-adjuvant | Yes No | 257 | *3.4**97* | 17 | *100* |
| Debulking | OptimalSuboptimal | 2930 | *49**51* | 125 | *71**29* |
| Series | 1982920565261939899 | 313340 | *5.1**22**5.1**68* | 413 | *24**77* |
| 1 year survival (95% CI) | 97% (92-100) | 94% (84-100) |
| 3 year survival (95% CI) | 82% (73-94) | 62% (41-93) |
| 5 year survival (95% CI) | 64% (50-80) | 33% (14-77) |
| Median survival (95% CI) | 2267 (1860-NA) | 1403 (1088-NA) |

F. Clinicopathological parameters for subgroups defined by node 6 (TC 250 / ECM interactions)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 7 ( Age) |  | ≤53.7 (#) | % | > 53.7 (#) | % |
| Age, mean (range) |  | 48 (39-54) | 64 (54-87) |
| Taxol treated | Yes No | 145 | *74**26* | 337 | *83**18* |
| Neo-adjuvant | Yes No | 118 | *5**95* | 139 | *2.5**98* |
| Debulking | OptimalSuboptimal | 415 | *21**79* | 2515 | *63**38* |
| Series | 1982920565261939899 | 910 | *47**53* | 34310 | *7.5**10**7.5**25* |
| 1 year survival (95% CI) | 100 (NA-100) | 95% (89-100) |
| 3 year survival (95% CI) | 77 (59-100) | 87 (75-98) |
| 5 year survival (95% CI) | 44 (24-77) | 77 (63-94) |
| Median survival (95% CI) | 1663 (1415-NA) | 2784 (2227-NA) |

G. Clinicopathological parameters for subgroups defined by node 7 (Age)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 8 (TC 76 / 9p13-p21 / Replication stress) |  | Low (#) | % | High (#) | % |
| Age, mean (range) |  | 52 (23-68) | 60 (35-80) |
| Taxol treated | Yes No | 20 | *100* | 1552 | *22**78* |
| Neo-adjuvant | Yes No | 20 | *100* | 364 | *4.5**96* |
| Debulking | OptimalSuboptimal | 119 | *55**45* | 2938 | *43**57* |
| Series | 20565261939899 | 3116 | *15**5**80* | 13252 | *19**3**78* |
| 1 year survival (95% CI) | 100% (NA-100) | 97% (93-100) |
| 3 year survival (95% CI) | 74% (57-97) | 46% (34-62) |
| 5 year survival (95% CI) | 54% (32-90) | 11% (4-28) |
| Median survival (95% CI) | 2284 (1274-NA) | 1024 (854-1233) |

H. Clinicopathological parameters for subgroups defined by node 8 (TC 76 / 9p13-p21 / Replication stress)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 9 (TC 146 / Neurotransmitter signaling) |  | Low (#) | % | High (#) | % |
| Age, mean (range) | 57 (35-80) | 63 (46-80) |
| Taxol treated | Yes No | 326 | *84**16* | 209 | *69**31* |
| Neo-adjuvant | Yes No | 236 | *5.3**95* | 128 | *3.4**97* |
| Debulking | OptimalSuboptimal | 1523 | *40**61* | 1415 | *48**52* |
| Series | 20565261939899 | 731 | *18**82* | 6221 | *21**6.9**72* |
| 1 year survival (95% CI) | 100% (NA-100) | 93% (84-100) |  |  |
| 3 year survival (95% CI) | 62% (46-83) | 26% (13-53) |
| 5 year survival (95% CI) | 14% (4-44) | 7% (1-41) |
| Median survival (95% CI) | 1159 (1034-1392) | 735 (641-1159) |

I. Clinicopathological parameters for subgroups defined by node 9 (TC 146 / Neurotransmitter signaling)